Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Adriana Prawak

Sports Medicine Havertown, PA Doctor of Osteopathy

NPI 1801824354 CMS profile 81313

525 W Chester Pike, Suite 203, Havertown, PA 19083

Open in the dashboard

General payments

$1,659

91 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adriana Prawak of Havertown, PA is reported in the CMS Open Payments database as having received $1,659 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $149 7
2024 General $66 2
2023 General $44 2
2022 General $58 3
2021 General $252 13
2020 General $350 19
2019 General $741 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adriana Prawak
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Adriana Prawak were reported at $149. Among 250 Sports Medicine profiles paid that year, the median was $119 and the middle half received between $39 and $268.

Show as a table
Year Adriana Prawak Sports Medicine median Middle half National median
2019 $741 $125 $45–$345 $163
2020 $350 $96 $33–$311 $114
2021 $252 $113 $34–$344 $132
2022 $58 $100 $35–$293 $149
2023 $44 $100 $42–$324 $160
2024 $66 $139 $45–$319 $164
2025 $149 $119 $39–$268 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Collegium Pharmaceutical, Inc. $272 14 payments
  2. Flexion Therapeutics, Inc. $203 12 payments
  3. Scilex Pharmaceuticals Inc. $133 7 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $92 6 payments
  5. Arbor Pharmaceuticals, Inc. $88 6 payments
  6. SI-BONE, Inc. $72 2 payments
  7. Bioventus LLC $66 2 payments
  8. DePuy Synthes Sales Inc. $63 4 payments
  9. Pfizer Inc. $56 5 payments
  10. Fidia Pharma USA Inc. $54 3 payments
  11. Other $558 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,659 91 payments
Products named General payments · program years 2019–2025
  1. Zilretta $203 12 payments
  2. XTAMPZA $165 9 payments
  3. BELBUCA $107 5 payments
  4. RELISTOR $92 6 payments
  5. ZTLido $81 4 payments
  6. IFUSE IMPLANT $72 2 payments
  7. Durolane $66 2 payments
  8. LYRICA $56 5 payments
  9. HYMOVIS $54 3 payments
  10. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $52 3 payments
  11. Other $884 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

1,484

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$76,867

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

17.2%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 30 $30,753
Xtampza Er Oxycodone Myristate Brand 12 $8,174
Belbuca Buprenorphine Hcl Brand 12 $7,837
Diclofenac Sodium Generic 38 $5,527
Oxycodone Hcl Generic 127 $2,948
Lidocaine Generic 27 $2,902
Fentanyl Generic 37 $2,794
Pregabalin Generic 107 $2,691
Gabapentin Generic 194 $2,058
Morphine Sulfate Er Morphine Sulfate Brand 56 $1,487

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$194,719

Of which drugs: $44,911

Medicare patients

324

Average age 74

Services billed

7,185

216 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 32%
Diabetes 27%
Osteoporosis 27%
Depression 26%
Chronic kidney disease 19%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 23 1,440 $19,718
Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 Office 22 40 $16,329
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 168 2,445 $217
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 111 $87
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 76 199 $58
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 112 503 $54

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BELBUCA
  • Collegium Pharmaceutical, Inc. $23
$23 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record